Hansa Raises $121m To Fund Idefirix Launch
Big Plans For Antibody-Cleaving Enzyme
Executive Summary
Having recently signed a gene therapy collaboration with Sarepta and received a positive opinion from the CHMP for its kidney transplant therapy, Sweden's Hansa has now raised a substantial sum in a "multiple times oversubscribed" placing.
You may also be interested in...
Hansa Biopharma To Be Transformed By Idefirix Approval In EU
With the first approval in the bag for its lead product, Idefirix, from the European Commission, Sweden’s Hansa Biopharma is planning to launch the product in Europe using its own medical and commercial organization in core markets.
Sarepta’s Gene Therapy Impresses In Limb-Girdle Muscular Dystrophy
Positive functional results from Sarepta’s SRP-9003 gene therapy in limb-girdle muscular dystrophy type 2E bodes well for a pivotal study, and for the company’s studies of other potential gene therapies in Duchenne muscular dystrophy.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.